FDA inspection
Sun Pharmaceutical Industries (prev. Ranbaxy): FDA inspection ending Feb 25, 2006
FDA inspection 420149 · Official Action Indicated (OAI) · Sirmaur
Key facts
| Inspection ID | 420149 |
|---|---|
| Firm | Sun Pharmaceutical Industries (prev. Ranbaxy) |
| FEI number | 3002807978 |
| Address | Village Ganguwala, Tehsil-Paonta Sahib |
| City | Sirmaur |
| Fiscal year | 2006 |
| Inspection end date | Feb 25, 2006 |
| Classification | Official Action Indicated (OAI) |
| Project area | Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs |
| Product type | Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data